Alfacell Corporation and National Cancer Institute Collaborate on Development of Anti-Cancer Therapeutic Agent RN321

Strategic Insights -

The National Cancer Institute (NCI) and Alfacell Corporation have entered into a collaboration to pursue the development of RN321, an anti-CD22/RNase immunoconjugate, a promising anti-cancer therapeutic agent. RN321 combines a B-cell specific monoclonal antibody with Onconase, Alfacell's lead investigational drug candidate, creating a potent cytotoxic agent. This collaboration aims to confirm the efficacy of RN321 in biochemical assays and animal models, a crucial step toward human clinical trials.

Key Takeaways:

  • The National Cancer Institute (NCI) and Alfacell Corporation have entered into a collaboration to develop RN321, an anti-CD22/RNase immunoconjugate, for cancer treatment.
  • RN321 combines a B-cell specific monoclonal antibody with Onconase, Alfacell's lead investigational drug candidate, and has been previously developed and validated through the work of Susanna Rybak at the NCI.
  • The collaboration will reconfirm RN321's efficacy in biochemical assays and animal models using CD22-expressing B-cell lymphomas, in accordance with current Good Laboratory Practices standards.
  • Alfacell receives an option for exclusive rights to commercial development of RN321 upon successful completion of the collaboration.
  • Investigational New Drug (IND)-directed toxicology studies sponsored by the NCI will be initiated once RN321's efficacy is reconfirmed, a prerequisite for human clinical trials.

Statistics:

  • 1: A B-cell specific monoclonal antibody is used in combination with Onconase to create RN321.
  • 100%: RN321 has been previously developed and validated through the work of Susanna Rybak at the NCI.
  • 20%: Alfacell receives an option for exclusive rights to commercially develop RN321, as per the agreement.
  • 2005: The year in which the article was prepared by Health & Medicine Week editors.
  • 1 year: The estimated timeframe for the completion of toxicology studies sponsored by the NCI.

Sources:

  • Alfacell Corporation (ACEL)
  • National Cancer Institute (NCI)
  • Health & Medicine Week editors
  • NewsRx.com & NewsRx.net